Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
ABACUS is a single arm phase 2 study that investigated 2 cycles of atezolizumab (1200mg Q3) prior to cystectomy in 95 patients with muscle invasive transitional cell cancer (T2-4N0M0). Pathological complete response (pCR) occurring in ≥20% of patients was the primary endpoint. Biomarker analysis on sequential tissue was a co-primary endpoint.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001006199 | - | ||
EGAD00001006200 | - | ||
EGAD00001006201 | - | ||
EGAD00001006205 | Illumina HiSeq 2500 | 148 | |
EGAD00001007578 | - | ||
EGAD00001007579 | - | ||
EGAD00001007652 | - |
Publications | Citations |
---|---|
Transcriptomic signatures of tumors undergoing T cell attack.
Cancer Immunol Immunother 71: 2022 553-563 |
5 |
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun 14: 2023 2126 |
19 |
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy.
J Immunother Cancer 11: 2023 e006941 |
3 |
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Nat Commun 15: 2024 1349 |
3 |
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Nat Commun 15: 2024 4448 |
1 |